Clinical Trials/NCT00696449

NCT00696449

Completed

Phase 4

An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris

Wake Forest University1 site in 1 country61 target enrollmentJune 2006

ConditionsAcne Vulgaris

InterventionsAdapalene frequent visits electronic reminder Parent reminder Standard of care

DrugsAdapalene

Overview

Phase: Phase 4
Intervention: Adapalene
Conditions: Acne Vulgaris
Sponsor: Wake Forest University
Enrollment: 61
Locations: 1
Primary Endpoint: Adherence to Treatment
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The primary objective of this study is to investigate potential differences between four treatment intervention groups in the adherence to treatment with Differin® Gel, 0.1%. Differin is approved by the Food and Drug Administration (FDA) to treat acne.

Detailed Description

Subjects will be enrolled and randomized in a 1:1:1:1 ratio to one of four treatment intervention groups. All Subjects will be treated once-daily for 12 weeks with Differin® Gel, 0.1%. The four intervention groups were designated according to follow-up strategies as follows: * More frequent than normal office visits * Electronic reminders (voice, e-mail, text messages) * Parental involvement/intervention reminders * No intervention or reminders

Registry

clinicaltrials.gov

Start Date

June 2006

End Date

October 2009

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Wake Forest University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male or female Subjects of any race, aged 13 to 18 years inclusive,
•Subjects with a diagnosis of moderate to severe Acne vulgaris, measured by lesion counts of a minimum of 15 and a maximum of 50 inflammatory lesions (papules and pustules) on the face, AND a minimum of 30 and a maximum of 125 total lesions. Subjects with nodules may participate in the study.
•Female Subjects of childbearing potential must have a negative urine pregnancy test (UPT).
•Female Subjects of childbearing potential must practice a highly effective method of contraception during the study
•Subjects (and parent/guardian if Subject is under 18 years of age) must be willing and capable of following study instructions to the extent and degree required by the protocol;
•Subjects able to follow study instructions and likely to complete all required visits;
•Subjects/Representative signs the Informed Consent prior to any study procedures. Subjects under the age of 18 must have one parent or guardian read and sign the Informed Assent Form prior to receiving study treatment but the parent(s) or guardian is not required to attend the follow-up visits unless requested;
•Subject must be willing to be photographed and sign a release form allowing photographs to be used.

Exclusion Criteria

•Female Subjects who are pregnant, nursing or planning a pregnancy during the study,
•Subjects with a condition or who are in a situation which, in the Investigator's opinion, may put the Subject at risk, may confound the study results, or may interfere with the Subject's participation in the study,
•Subjects with known allergy to one of the components of the test products,
•Subjects who have participated in another investigational drug or device research study within 30 days of enrolment, Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or or severe acne requiring more than topical treatment (e.g. oral isotretinoin);
•Subjects with a beard or other facial hair that might interfere with study assessments;
•Subjects with underlying diseases or other dermatological conditions that require the use of interfering topical or systemic therapy such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea;
•Subjects who are at risk in terms of precautions, warnings, and contra-indication (see package insert for Differin Gel, 0.1%);
•Subjects who foresee intensive UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.);
•Subjects with a known history of drug and/or alcohol abuse.

Arms & Interventions

Frequent visits

This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.

Intervention: Adapalene

Frequent visits

Intervention: frequent visits

Electronic reminder

This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.

Intervention: Adapalene

Electronic reminder

Intervention: electronic reminder

Parent reminder

In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.

Intervention: Adapalene

Parent reminder

Intervention: Parent reminder

Standard of care

This group is considered to be the "standard of care" arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits.

Intervention: Adapalene